Zenas BioPharma (ZBIO) Debt to Equity (2025 - 2026)

Zenas BioPharma (ZBIO) recorded quarterly Debt to Equity of $0.21 in Q1 2026, down 33.9% quarter-over-quarter from $0.32 in Q4 2025.

Zenas BioPharma (ZBIO) Debt to Equity (2025 - 2026) Analysis & Trends

Zenas BioPharma's Debt to Equity history runs 2 years deep, the most recent figure standing at $0.21 for Q1 2026.

In Q1 2026, Debt to Equity changed N/A year-over-year to $0.21; the TTM figure through Mar 2026 stood at $0.21 (changed N/A YoY), while the FY2025 annual figure was $0.32, changed N/A from the prior year.
Debt to Equity was $0.21 for Q1 2026 at Zenas BioPharma, down from $0.32 in the prior quarter.
In the past five years, Debt to Equity ranged from a high of $0.37 in Q3 2025 to a low of $0.21 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	0.32
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Zenas BioPharma	1.10 Bn	379.43 Mn	-	0.21

Download Data